{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:54:45Z","timestamp":1790963685676,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI P30CA023108"],"award-info":[{"award-number":["NCI P30CA023108"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Immunext"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00262-018-2169-1","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T02:52:41Z","timestamp":1525747961000},"page":"1113-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival"],"prefix":"10.1007","volume":"67","author":[{"given":"Lawrence F.","family":"Kuklinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolph J.","family":"Noelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina V.","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"issue":"1","key":"2169_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","volume":"16","author":"C Garbe","year":"2011","unstructured":"Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16(1):5\u201324","journal-title":"Oncologist"},{"issue":"1","key":"2169_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1067\/mjd.2003.9","volume":"48","author":"AC Geller","year":"2003","unstructured":"Geller AC, Zhang Z, Sober AJ, Halpern AC, Weinstock MA, Miller DR et al (2003) The first 15\u00a0years of the American Academy of Dermatology skin cancer screening programs: 1985\u20131999. J Am Acad Dermatol 48(1):34\u201341","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl 1","key":"2169_CR3","first-page":"S17","volume":"65","author":"A Jemal","year":"2011","unstructured":"Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J et al (2011) Recent trends in the cutaneous melanoma incidence and death rates in the United States, 1992\u20132006. J Am Acad Dermatol 65(5 Suppl 1):S17\u2013S25 (e1\u20133)","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"2169_CR4","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622\u20133634","journal-title":"J Clin Oncol"},{"issue":"7","key":"2169_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","volume":"77","author":"CG Clemente","year":"1996","unstructured":"Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303\u20131310","journal-title":"Cancer"},{"issue":"3","key":"2169_CR6","first-page":"705","volume":"29","author":"WH Clark Jr","year":"1969","unstructured":"Clark WH Jr, From L, Bernardino EA et al (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29(3):705\u2013727","journal-title":"Cancer Res"},{"issue":"21","key":"2169_CR7","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","volume":"30","author":"F Azimi","year":"2012","unstructured":"Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW et al (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sential lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30(21):2678\u20132683","journal-title":"J Clin Oncol"},{"issue":"127","key":"2169_CR8","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37","journal-title":"Sci Transl Med"},{"issue":"7","key":"2169_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al (2000) Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027\u20131034","journal-title":"J Exp Med"},{"issue":"3","key":"2169_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.20100619","volume":"208","author":"L Wang","year":"2011","unstructured":"Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208(3):577\u2013592","journal-title":"J Exp Med"},{"issue":"7","key":"2169_CR11","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","volume":"74","author":"JL Lines","year":"2014","unstructured":"Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O\u2019Connell S et al (2014) VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74(7):1924\u20131932","journal-title":"Cancer Res"},{"issue":"4","key":"2169_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.4049\/jimmunol.1100660","volume":"187","author":"DB Flies","year":"2011","unstructured":"Flies DB, Wang S, Xu H, Chen L (2011) Cutting edge: a monoclonal antibody specific for programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol 187(4):1537\u20131541","journal-title":"J Immunol"},{"issue":"6","key":"2169_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","volume":"2","author":"JL Lines","year":"2014","unstructured":"Lines JL, Sempere LF, Broughton T, Wang L, Noelle R (2014) VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2(6):510\u2013517","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2169_CR14","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","volume":"74","author":"I Le Mercier","year":"2014","unstructured":"Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P et al (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res 74(7):1933\u20131944","journal-title":"Cancer Res"},{"issue":"6","key":"2169_CR15","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/cncr.21283","volume":"104","author":"F Piras","year":"2005","unstructured":"Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C et al (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104(6):1246\u20131254","journal-title":"Cancer"},{"issue":"7","key":"2169_CR16","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"The Cancer Genome Atlas Network","year":"2015","unstructured":"The Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681\u20131696","journal-title":"Cell"},{"issue":"5","key":"2169_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","volume":"66","author":"L Wu","year":"2017","unstructured":"Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Lao L et al (2017) Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 66(5):627\u2013636","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"2169_CR18","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III and IV melanoma. N Engl J Med 377(19):1824\u20131835","journal-title":"N Engl J Med"},{"issue":"19","key":"2169_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845\u20131855","journal-title":"N Engl J Med"},{"issue":"4","key":"2169_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2169_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275\u2013287","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2169_CR22","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/cncr.24899","volume":"116","author":"R Hino","year":"2010","unstructured":"Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T et al (2010) Tumor expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757\u20131766","journal-title":"Cancer"},{"issue":"1","key":"2169_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/labinvest.2013.130","volume":"94","author":"V Velcheti","year":"2014","unstructured":"Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M et al (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 94(1):107\u2013116","journal-title":"Lab Investig"},{"issue":"8","key":"2169_CR24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8):1537\u20131544","journal-title":"Blood"},{"issue":"5","key":"2169_CR25","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.jaad.2014.01.880","volume":"70","author":"J Oba","year":"2014","unstructured":"Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M (2014) Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. J Am Acad Dermatol 70(5):954\u2013956","journal-title":"J Am Acad Dermatol"},{"issue":"7528","key":"2169_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571","journal-title":"Nature"},{"issue":"3","key":"2169_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245\u2013253","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"2169_CR28","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1038\/s41598-017-06410-w","volume":"7","author":"Q Wang","year":"2017","unstructured":"Wang Q, He J, Flies DB, Luo L, Chen L (2017) Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability. Sci Rep 7(1):6086","journal-title":"Sci Rep"},{"issue":"21","key":"2169_CR29","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.1420370112","volume":"112","author":"J Liu","year":"2015","unstructured":"Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD et al (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci USA 112(21):6682\u20136687","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2169_CR30","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/cncr.25747","volume":"117","author":"J Gadiot","year":"2011","unstructured":"Gadiot J, Hoojikaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117(10):2192\u20132201","journal-title":"Cancer"},{"issue":"7","key":"2169_CR31","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381\u20133385","journal-title":"Cancer Res"},{"issue":"1","key":"2169_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10549-016-4095-2","volume":"162","author":"JY Tsang","year":"2017","unstructured":"Tsang JY, Au WL, Lo KY, Ni YB, Hlaing T, Hu J et al (2017) PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Res Treat 162(1):19\u201330","journal-title":"Breast Cancer Res Treat"},{"issue":"48","key":"2169_CR33","doi-asserted-by":"publisher","first-page":"E7769","DOI":"10.1073\/pnas.1607836113","volume":"113","author":"L Danilova","year":"2016","unstructured":"Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H et al (2016) Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci USA 113(48):E7769\u2013E7777","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2169_CR34","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","volume":"30","author":"H Kakavand","year":"2017","unstructured":"Kakavand H, Jacket LA, Menzies AM, Gide TN, Carlino MS, Saw RPM et al (2017) Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol 30(12):1666\u20131676","journal-title":"Mod Pathol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2169-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2169-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2169-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T10:40:56Z","timestamp":1589625656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2169-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2169-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"24 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Randolph J. Noelle is the co-founder of ImmuNext. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Dartmouth College Committee for the Protection of Human Subjects\/Institutional Review Board, approval number 23388, and was in compliance with ethical guidelines according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived by the Institutional Review Board on the grounds of being a retrospective study using tumor tissue already archived by the Dartmouth-Hitchcock Medical Center Department of Pathology tumor bank. Many patients were deceased. All data was abstracted from the medical record and had previously been obtained for the purposes of medical care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}